OM
KZR

Opaleye Management’s Kezar Life Sciences KZR Stock Holding History

Opaleye Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-42,500
Closed -$506K – 50
2023
Q3 		$506K Buy
42,500
+32,620
+330% +$578K 0.16% 39
2023
Q2 		$242K Sell
9,880
-52,620
-84% -$1.37M 0.06% 47
2023
Q1 		$1.96M Buy
+62,500
New +$3.62M 0.59% 35
2021
Q3 		– Sell
-69,780
Closed -$3.79M – 52
2021
Q2 		$3.79M Sell
69,780
-1,340
-2% -$76.1K 0.63% 38
2021
Q1 		$4.24M Buy
71,120
+320
+0.5% +$18.7K 0.62% 44
2020
Q4 		$3.7M Buy
70,800
+3,000
+4% +$167K 0.48% 42
2020
Q3 		$3.28M Buy
+67,800
New +$3.24M 0.64% 39

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management's KZR Position: Q4 2023 in Review

Opaleye Management sold out of Kezar Life Sciences (KZR) in Q4 2023, closing a stake of 42,500 shares — an estimated $506K sold.

Opaleye Management first reported a position in KZR in Q3 2020 and held it in 7 quarters. The position peaked at $4.24M in Q1 2021. 81 funds tracked by Wall St. Rank hold KZR as of Q4 2023.

  • Opaleye Management reported no remaining Kezar Life Sciences position as of Q4 2023 after selling out during the quarter.
  • Opaleye Management sold 42,500 Kezar Life Sciences shares in Q4 2023, an estimated $506K.
  • Opaleye Management first reported a position in Kezar Life Sciences in Q3 2020 and held it in 7 quarters.
  • Opaleye Management's Kezar Life Sciences position peaked at $4.24M in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2023.

Based on Opaleye Management's 13F filing for Q4 2023, filed 14 Feb 2024.